-John D Minna Researcher Activity Profile

Research Author Detailed Information 

John D Minna Publication Rate By Year

John D Minna has published 1 paper(s) in 1981, 7 paper(s) in 2006, 26 paper(s) in 2007, 9 paper(s) in 2008, for a total of 43 research publications in total.

John D Jd Minna Author Information

LAST NAME: minna

FIRST NAME: John D

INITIALS: jd

AFFILIATION:

Papers

John D Minna's Publication Record

1. A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer. Year Published: 2007
Divisions of Thoracic Oncology and Internal Medicine, National Cancer Center Hospital, Tokyo, Japan.
2. An ecological study of the association of metal air pollutants with lung cancer incidence in Texas. Year Published: 2007
Department of Internal Medicine, Hamon Center for Therapeutic Oncology Research, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390-9103, USA. yvonne.coyle@utsouthwestern.edu
3. Establishment and expression profiling of new lung cancer cell lines from Chinese smokers and lifetime never-smokers. Year Published: 2007
University Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR, China.
4. A translational view of the molecular pathogenesis of lung cancer. Year Published: 2007
Hamon Center for Therapeutic Oncology Research Simmons Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
5. c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells. Year Published: 2007
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
6. Methods for detecting DNA methylation in tumors: from bench to bedside. Year Published: 2007
The Hamon Center of Therapeutic Oncology Research and the Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX, USA.
7. Homozygous deletion and reduced expression of the DOCK8 gene in human lung cancer. Year Published: 2006
Division of Biology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
8. A three-dimensional model of differentiation of immortalized human bronchial epithelial cells. Year Published: 2006
Department of Biology, University of Central Oklahoma, Edmond, OK, USA.
9. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Year Published: 2006
Division of Molecular Radiation Biology, Department of Radiation Oncology, University of Texas Southwestern Medical Center, 2201 Inwood Road, NC 7.208, Mail Code 9187, Dallas, TX 75390, USA.
10. The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Year Published: 2006
Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
11. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. Year Published: 2006
Hamon Center for Therapeutic Oncology Research, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States of America.
12. DNA methylation in health, disease, and cancer. Year Published: 2007
Hamon Center for Therapeutic Oncology Research NB8.206, The University of Texas Southwestern Medical Center at Dallas, 6000 Harry Hines Blvd., Dallas, TX 75390-8593, USA.
13. Methylation and gene silencing of the Ras-related GTPase gene in lung and breast cancers. Year Published: 2007
Department of Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
14. Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. Year Published: 2007
Department of Medicine, University of Hong Kong, HKSAR, China.
15. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Year Published: 2007
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
16. sIR: siRNA Information Resource, a web-based tool for siRNA sequence design and analysis and an open access siRNA database. Year Published: 2007
Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA. jyotikshah@hotmail.com <jyotikshah@hotmail.com>
17. Genes regulating the sensitivity of solid tumor cell lines to cytotoxic agents: a literature review. Year Published: 2007
Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. isekine@ncc.go.jp
18. Tumor suppressor 101F6 and ascorbate synergistically and selectively inhibit non-small cell lung cancer growth by caspase-independent apoptosis and autophagy. Year Published: 2007
Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
19. The DRD2 TaqI-B polymorphism and its relationship to smoking abstinence and withdrawal symptoms. Year Published: 2007
Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77230-1439, USA. jdrobinson@mdanderson.org
20. Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized. Year Published: 2007
Department of Biochemistry, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390, USA.
21. Seizure 6-like (SEZ6L) gene and risk for lung cancer. Year Published: 2007
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA.
22. Homozygous deletion scanning of the lung cancer genome at a 100-kb resolution. Year Published: 2007
Biology Division, National Cancer Center Research Institute, Tokyo, Japan.
23. Tumor mRNA expression profiles predict responses to chemotherapy. Year Published: 2007
24. New molecularly targeted therapies for lung cancer. Year Published: 2007
Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
25. EGFR signaling is required for TGF-beta 1 mediated COX-2 induction in human bronchial epithelial cells. Year Published: 2007
Lung Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California 90095, USA.
26. Fragile histidine triad-mediated tumor suppression of lung cancer by targeting multiple components of the Ras/Rho GTPase molecular switch. Year Published: 2007
Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
27. Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized. Year Published: 2007
Department of Biochemistry, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390, USA.
28. Characterizing the cancer genome in lung adenocarcinoma. Year Published: 2007
Department of Medical Oncology and Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
29. Characterizing the cancer genome in lung adenocarcinoma. Year Published: 2007
Department of Medical Oncology and Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
30. RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. Year Published: 2008
Hamon Center for Therapeutic Oncology Research, The University of Texas Southwestern Medical Center at Dallas, 6000 Harry Hines Boulevard, Dallas, TX 75390-8593, USA. boning.gao@utsouthwestern.edu
31. Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for Cisplatin resistance of human breast cancer cells. Year Published: 2008
Stiftung Center of Advanced European Studies and Research, Ludwig-Erhard-Allee 2, 53175 Bonn, Germany, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390-8593.
32. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Year Published: 2006
Drug Discovery, Incyte Corporation, Experimental Station, Route 141 and Henry Clay Road, Building 400, Wilmington, Delaware 19880, USA. binbing_s_zhou@yahoo.com
33. Characterizing the cancer genome in lung adenocarcinoma. Year Published: 2007
Department of Medical Oncology and Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
34. Silencing of HPV 18 oncoproteins With RNA interference causes growth inhibition of cervical cancer cells. Year Published: 2007
Division ofGynecologic Oncology, Hamon Center of Therapeutic Oncology Research, University ofTexas Southwestern Medical Center, Dallas, TX75390-9032, USA. jayanthi.lea@utsouthwestern.edu
35. Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. Year Published: 2008
Stiftung Center of Advanced European Studies and Research, Ludwig-Erhard-Allee 2, 53175 Bonn, Germany.
36. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Year Published: 2006
Division of Molecular Radiation Biology, Department of Radiation Oncology, University of Texas Southwestern Medical Center, 2201 Inwood Road, NC 7.208, Mail Code 9187, Dallas, TX 75390, USA.
37. IP6K2 is a client for HSP90 and a target for cancer therapeutics development. Year Published: 2008
The Hamon Center for Therapeutic Oncology Research, Simmons Cancer Center, and Departments of Pharmacology and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390.
38. IP6K2 is a client for HSP90 and a target for cancer therapeutics development. Year Published: 2008
The Hamon Center for Therapeutic Oncology Research, Simmons Cancer Center, and Departments of Pharmacology and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
39. Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Year Published: 2008
Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.
40. Small cell lung cancer: radionuclide bone scans for assessment of tumor extent and response. Year Published: 1981
41. RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. Year Published: 2008
Hamon Center for Therapeutic Oncology Research, The University of Texas Southwestern Medical Center at Dallas, 6000 Harry Hines Boulevard, Dallas, TX 75390-8593, USA. boning.gao@utsouthwestern.edu
42. Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Year Published: 2008
Department of Thoracic/Head and Neck Medical Oncology, University of Texas-M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
43. Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Year Published: 2008
Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.